Ivosidenib: A Review in Advanced Cholangiocarcinoma

Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study.

(2022) Christina X. Chamberlain et al.   JOURNAL OF CLINICAL ONCOLOGY

Biology of IDH mutant cholangiocarcinoma

(2022) Meng‐Ju Wu et al.   HEPATOLOGY

Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study

(2022) Yong-Pyo Lee et al.   Cancers

Precision Medicine in Cholangiocarcinoma: Past, Present, and Future

(2022) Chi-Yuan Cheng et al.   Life-Basel

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors

(2022) Raphael Reinbold et al.   Nature Communications

Oncometabolite d -2HG alters T cell metabolism to impair CD8 + T cell function

(2022) Giulia Notarangelo et al.   SCIENCE

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis

(2022) Margherita Rimini et al.   Targeted Oncology

Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

(2022) A. Vogel et al.   ANNALS OF ONCOLOGY

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma

(2022) Gajanan Kendre et al.   JOURNAL OF HEPATOLOGY

Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

(2021) Andrew X. Zhu et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-IDH1 cholangiocarcinoma

(2021) Elia Aguado-Fraile et al.   Future Oncology

IDH1 and IDH2 Driven Intrahepatic Cholangiocarcinoma (IHCC): A comprehensive genomic and immune profiling study.

(2021) Shalini Makawita et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation

(2021) Andrew X. Zhu et al.   JAMA Oncology

Mutant IDH Inhibits IFNγ–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma

(2021) Meng-Ju Wu et al.   Cancer Discovery

Cholangiocarcinoma: new perspectives for new horizons

(2021) Margherita Rimini et al.   Expert Review of Gastroenterology & Hepatology

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Oral Ivosidenib in Otherwise Healthy Participants

(2020) Bin Fan et al.   Clinical Pharmacology in Drug Development

Medical treatment for cholangiocarcinoma

(2019) Jorge Adeva et al.   LIVER INTERNATIONAL

Pharmacokinetics, absorption, metabolism, and excretion of [14C]ivosidenib (AG-120) in healthy male subjects

(2019) Chandra Prakash et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects

(2019) David Dai et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

(2019) Maeve A Lowery et al.   Lancet Gastroenterology & Hepatology

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

(2018) Janeta Popovici-Muller et al.   ACS Medicinal Chemistry Letters

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

(2014) Supriya K. Saha et al.   NATURE

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE